Press Releases

06.07.2017

Sangamo Therapeutics And Pfizer Announce That Sb-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency

06.06.2017

Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy

06.04.2017

Spark Therapeutics Presents Updated Preliminary Data From Hemophilia B Phase 1/2 Trial Suggesting Consistent And Sustained Levels Of Factor IX Activity At The Hemostasis And Thrombosis Research Society (HTRS) 2017 Scientific Symposium

06.03.2017

Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer

05.31.2017

Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT® (sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery

05.30.2017

European Commission Approves Pfizer’s TRUMENBA® to Help Prevent Meningococcal Group B Disease in Adolescents and Adults

05.25.2017

FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications

05.24.2017

Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Corporation

05.22.2017

Pharma Completes Patient Recruitment Of Recombinant Human Alkaline Phosphatase (Recap) Phase II Trial In Acute Kidney Injury

05.17.2017

Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting

05.17.2017

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017

05.17.2017

Pfizer Invites Public to View and Listen to Webcast of June 9 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations